
    
      In stage I, VAQTA™ given concomitantly with Infanrix™ and/or PedvaxHIB™ was evaluated.

      In stage 2: Two (2) doses of the VAQTA™ vaccine were administered at least 6 months apart.
      Safety data was collected after each dose.
    
  